Genflow boosts SIRT6 patent portfolio, eyes dog trial results this month

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire tells Proactive's Stephen Gunnion that accelerated US patent examination for its centenarian-derived SIRT6 gene variant strengthens protection across the company's entire therapeutic pipeline. Its MASH-related patent application has also been published, while the corresponding European application nears grant. Leire explained that building multiple layers of IP protection around SIRT6 and its applications is key to attracting commercial partners, particularly in Genflow's animal health discussions: "These patent milestones therefore strengthen our position as we continue to discuss with potential partners." On the dog clinical trial, Leire said biological age results from a UCLA spin-off lab were delayed by logistics but are now being processed, with data expected by the end of August. Looking ahead, he points to continued patent progress, advancement of the MASH programme, dog trial results and business development around the company's glaucoma programme. For more interviews with company leaders and market insights, visit the Proactive YouTube channel. If you enjoyed this video, please give it a like, subscribe to the channel and enable notifications so you never miss future updates. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #GenflowBiosciences #SIRT6 #Biotech #Patent #USPTO #MASH #MetabolicDisease #GeneTherapy #Longevity #DrugDevelopment #AnimalHealth #ClinicalTrials #Biotechnology #HealthcareInnovation #ProactiveInvestors